Litcius/Paper detail

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Tina Albertson, Jacob Garcia, Ana Kostić, Mary Mallaney, K. OGASAWARA, Kathryn J. Newhall, Yeonhee Kim, D. Li, Tanya Siddiqi

2020The Lancet2,332 citationsDOI

Topics & Concepts

Refractory (planetary science)MedicineInternal medicineOncologyLymphomaBiologyAstrobiologyCAR-T cell therapy researchLymphoma Diagnosis and TreatmentCutaneous lymphoproliferative disorders research
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study | Litcius